Related Experiment Video
Updated: Aug 5, 2026

13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
De novo design of selective kinase modulators
Biorxiv : the Preprint Server for Biology
|July 29, 2026
Summary
Researchers developed novel genetically encoded miniproteins to precisely control focal adhesion kinase (FAK) activity. These miniproteins can activate or inhibit FAK signaling in cells, offering a new platform for kinase modulation.
Area of Science:
- Molecular Biology
- Biochemistry
- Cell Signaling
Background:
- Protein kinases regulate cellular processes but are difficult to modulate due to conserved structures.
- Targeting kinase activity precisely is crucial for understanding and manipulating cell signaling pathways.
Purpose of the Study:
- To design genetically encoded miniproteins for precise activation or inhibition of focal adhesion kinase (FAK).
- To establish a versatile platform for selective, genetically encoded kinase control.
Main Methods:
- De novo design of genetically encoded miniproteins targeting the FAK kinase domain.
- Biochemical characterization of miniprotein binders for FAK activity modulation.
- In vitro and in-cell validation of miniprotein efficacy and specificity.
Main Results:
- 96 miniprotein binders were designed, with 33 modulating FAK activity.
- Four potent modulators were identified: two inhibitors with low-nanomolar IC50 values and two activators.
- Designed modulators demonstrated conserved inhibitory and activating effects in vitro and in living cells.
- FAK inhibitors were successfully redesigned to inhibit Src kinase, demonstrating platform versatility.
Conclusions:
- Designed conformational binders can directly tune FAK signaling in living cells.
- This approach provides a versatile platform for selective and genetically encoded kinase control.
- The study offers a starting point for discovering novel kinase modulatory sites.
Related Concept Videos
M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Protein Kinases and Phosphatases
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...

